NATIONAL INSTITUTES OF HEALTH
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Subsidiary, Private
- Established
- 1948-01-01
- Employees
- 1K
- Market Cap
- -
- Website
- http://www.nidcr.nih.gov
Sorafenib With or Without Paclitaxel and Carboplatin in Treating Patients With Recurrent Ovarian Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer
Phase 2
Completed
- Conditions
- Recurrent Ovarian CarcinomaRecurrent Fallopian Tube CarcinomaRecurrent Primary Peritoneal Carcinoma
- Interventions
- First Posted Date
- 2004-11-09
- Last Posted Date
- 2022-02-08
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 44
- Registration Number
- NCT00096200
- Locations
- 🇺🇸
Moffitt Cancer Center at Tampa General Hospital, Tampa, Florida, United States
🇺🇸Moffitt Cancer Center, Tampa, Florida, United States
🇺🇸Case Western Reserve University, Cleveland, Ohio, United States
Fluorouracil, Leucovorin, and Oxaliplatin With or Without Bevacizumab in Treating Patients Who Have Undergone Surgery for Stage II or Stage III Colon Cancer
Phase 3
Completed
- Conditions
- Colon AdenocarcinomaStage IIA Colon Cancer AJCC v7Stage IIB Colon Cancer AJCC v7Stage IIC Colon Cancer AJCC v7Stage IIIC Colon Cancer AJCC v7Stage IIIA Colon Cancer AJCC v7Stage IIIB Colon Cancer AJCC v7
- Interventions
- First Posted Date
- 2004-11-09
- Last Posted Date
- 2019-07-30
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 2710
- Registration Number
- NCT00096278
- Locations
- 🇺🇸
National Surgical Adjuvant Breast and Bowel Project, Pittsburgh, Pennsylvania, United States
Tanespimycin and Bortezomib in Treating Patients With Advanced Solid Tumors or Lymphomas
Phase 1
Terminated
- Conditions
- Adult Grade III Lymphomatoid GranulomatosisAIDS-related Peripheral/Systemic LymphomaAnaplastic Large Cell LymphomaAngioimmunoblastic T-cell LymphomaExtranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid TissueNodal Marginal Zone B-cell LymphomaRecurrent Adult Burkitt LymphomaRecurrent Adult Diffuse Large Cell LymphomaRecurrent Adult Diffuse Mixed Cell LymphomaRecurrent Adult Diffuse Small Cleaved Cell Lymphoma
- Interventions
- First Posted Date
- 2004-11-09
- Last Posted Date
- 2014-02-24
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 36
- Registration Number
- NCT00096005
- Locations
- 🇺🇸
Mayo Clinic, Rochester, Minnesota, United States
Radiotherapy Combined With Oxaliplatin and Fluorouracil Followed By Gemcitabine in Treating Patients With Locally Advanced, Unresectable Pancreatic Cancer
Phase 2
Completed
- Conditions
- Adenocarcinoma of the PancreasStage II Pancreatic CancerStage III Pancreatic Cancer
- Interventions
- First Posted Date
- 2004-11-09
- Last Posted Date
- 2013-07-16
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 50
- Registration Number
- NCT00096070
- Locations
- 🇺🇸
North Central Cancer Treatment Group, Rochester, Minnesota, United States
Sorafenib and Gemcitabine in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer
Phase 2
Completed
- Conditions
- Adenocarcinoma of the PancreasRecurrent Pancreatic CancerStage II Pancreatic CancerStage III Pancreatic CancerStage IV Pancreatic Cancer
- Interventions
- First Posted Date
- 2004-11-09
- Last Posted Date
- 2013-07-02
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 35
- Registration Number
- NCT00095966
- Locations
- 🇺🇸
University of Chicago Comprehensive Cancer Center, Chicago, Illinois, United States
Sorafenib Tosylate and Gemcitabine Hydrochloride in Treating Patients With Recurrent Epithelial Ovarian Cancer
Phase 2
Completed
- Conditions
- Recurrent Ovarian Epithelial CancerRecurrent Primary Peritoneal Cavity Cancer
- Interventions
- First Posted Date
- 2004-11-09
- Last Posted Date
- 2013-06-13
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 33
- Registration Number
- NCT00096395
- Locations
- 🇨🇦
Princess Margaret Hospital Phase 2 Consortium, Toronto, Ontario, Canada
Idarubicin and Cytarabine With or Without Bevacizumab in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia
Phase 2
Terminated
- Conditions
- Adult Acute Basophilic LeukemiaAdult Acute Eosinophilic LeukemiaAdult Acute Megakaryoblastic Leukemia (M7)Adult Acute Minimally Differentiated Myeloid Leukemia (M0)Adult Acute Monoblastic Leukemia (M5a)Adult Acute Monocytic Leukemia (M5b)Adult Acute Myeloblastic Leukemia With Maturation (M2)Adult Acute Myeloblastic Leukemia Without Maturation (M1)Adult Acute Myeloid Leukemia With 11q23 (MLL) AbnormalitiesAdult Acute Myelomonocytic Leukemia (M4)
- Interventions
- First Posted Date
- 2004-11-09
- Last Posted Date
- 2013-01-24
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 120
- Registration Number
- NCT00096148
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
3-AP and Gemcitabine in Treating Patients With Refractory Metastatic Breast Cancer
Phase 2
Terminated
- Conditions
- Male Breast CancerRecurrent Breast CancerStage IV Breast Cancer
- Interventions
- Other: laboratory biomarker analysisOther: pharmacological study
- First Posted Date
- 2004-11-09
- Last Posted Date
- 2013-01-16
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 68
- Registration Number
- NCT00095888
- Locations
- 🇺🇸
Mayo Clinic, Rochester, Minnesota, United States
Radiation Therapy and Stereotactic Radiosurgery With or Without Temozolomide or Erlotinib in Treating Patients With Brain Metastases Secondary to Non-Small Cell Lung Cancer
Phase 3
Terminated
- Conditions
- Recurrent Non-Small Cell Lung CarcinomaStage IV Non-Small Cell Lung Cancer AJCC v7Metastatic Malignant Neoplasm in the Brain
- Interventions
- Radiation: 3-Dimensional Conformal Radiation TherapyRadiation: Stereotactic Radiosurgery
- First Posted Date
- 2004-11-09
- Last Posted Date
- 2018-03-09
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 126
- Registration Number
- NCT00096265
- Locations
- 🇨🇦
McGill University Department of Oncology, Montreal, Quebec, Canada
🇺🇸Parkview Hospital Randallia, Fort Wayne, Indiana, United States
🇺🇸Integrated Community Oncology Network-Flager Cancer Center, Saint Augustine, Florida, United States
XK469R in Treating Patients With Refractory Hematologic Cancer
Phase 1
Completed
- Conditions
- Adult Acute Basophilic LeukemiaAdult Acute Eosinophilic LeukemiaAdult Acute Megakaryoblastic Leukemia (M7)Adult Acute Minimally Differentiated Myeloid Leukemia (M0)Adult Acute Monoblastic Leukemia (M5a)Adult Acute Monocytic Leukemia (M5b)Adult Acute Myeloblastic Leukemia With Maturation (M2)Adult Acute Myeloblastic Leukemia Without Maturation (M1)Adult Acute Myeloid Leukemia With 11q23 (MLL) AbnormalitiesAdult Acute Myeloid Leukemia With Inv(16)(p13;q22)
- Interventions
- First Posted Date
- 2004-11-09
- Last Posted Date
- 2013-02-08
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 60
- Registration Number
- NCT00095797
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States